



ACN 010 126 708

ASX Release  
13<sup>th</sup> April 2017

## DOPlify™ confirmed as World leading

### Highlights

- Independent University of Ghent benchmarking study results released confirming DOPlify™ is internationally competitive

**Adelaide, 13 April 2017:** Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the results from the University of Ghent’s comparison of single cell whole genome amplification kits have been presented at Cambridge Healthtech Institute’s Fifth International Molecular Diagnostics Europe in Lisbon 10-13 April. The results confirm that RHS’ DOPlify™ is World leading.

In the independent benchmarking comparison against 3 other modern single cell WGA kits, DOPlify™ excelled with 100% accuracy (sensitivity and specificity) for the detection of deletions and duplications from whole chromosomes down to 5Mb, matched only by Rubicon’s PicoPLEX DNA-seq. This resolution is important for preimplantation screening and circulating tumour cell applications. Rubicon was acquired in December 2016 by Takara Bio USA for approximately USD\$75m.

As indicated in the RHS ASX release of 16 December 2016, RHS welcomed the external independent analysis and were optimistic of the performance of DOPlify™ based on our internal and industry collaborative observations. While the independent Ghent study rated RHS’ DOPlify™ equivalent to PicoPLEX DNA-seq, RHS is strongly of the view that the ease of use, robustness and flexibility of DOPlify™ make it a superior product.

These competitive advantages have been met with great interest at the American Association for Cancer Research Annual Meeting 2017 in Washington DC April 1-5 at which RHS was an exhibitor and the 16<sup>th</sup> International Conference on Preimplantation Genetic Diagnosis, organized by the Preimplantation Genetic Diagnosis International Society in Valencia March 26-29 at which RHS gave 2 oral presentations and 3 posters and also exhibited.

The Company intends to provide a full market update in the near future, including details of a name change, which will be an agenda item the upcoming AGM planned for 26<sup>th</sup> May. The proposed name change reflects the Company’s increased scope of target markets beyond the IVF market.

#### For further information please contact:

**Dr Michelle Fraser**  
CEO and Managing Director  
Tel: (+61 8) 8152 9348  
[michelle.fraser@rhsc.com.au](mailto:michelle.fraser@rhsc.com.au)

**Dr David Brookes**  
Chairman  
Tel:(+61 8) 8152 9383  
[david.brookes@rhsc.com.au](mailto:david.brookes@rhsc.com.au)

## About Reproductive Health Science

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, with over 10 years of technical experience in the field. RHS recently released DOPlify™, a product that is a platform technology for whole genome amplification (WGA) of single or small numbers of cells. DOPlify™ is applicable to the global Next Generation Sequencing (NGS) market. EmbryoCollect™ is the Company's lead IVF specific product and is designed to increase the chance of a successful IVF cycle by selecting the most viable embryos for transfer by screening for aneuploidy. This is known as Preimplantation Genetic Screening (PGS).

### Reproductive Health Science Ltd.

ACN 010 126 708  
ASX: RHS

### Issued Capital

79.2 million shares  
6.9 million options

### Registered Office

Level One, BioSA Incubator,  
40-46 West Thebarton Road,  
Thebarton, SA 5031

---

**Tel:** +61 8 8152 9380

**Fax:** +61 8 8152 9474

**WEB** [www.rhsc.com.au](http://www.rhsc.com.au)

### Directors

Dr David Brookes (Chairman)  
Sue MacLeman  
Johnathon Matthews  
Dr Michelle Fraser (CEO)

### Finance Officer

**& Company Secretary**  
Raymond Ridge